The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ALEMBIC OSELTAMIVIR, ALEMVIR , ALEMZY , OSELEMBIC, OSELTAMIVIR AGH, OSELTAMIVIR AGHL, OSELTAMIVIR APPL , TAMIRAC (Alembic Pharmaceuticals Australia Pty Ltd)
Product name
ALEMBIC OSELTAMIVIR, ALEMVIR , ALEMZY , OSELEMBIC, OSELTAMIVIR AGH, OSELTAMIVIR AGHL, OSELTAMIVIR APPL , TAMIRAC
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
Oseltamivir phosphate
Registration type
New generic medicine
Indication
Oseltamivir phosphate is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.
Oseltamivir phosphate is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.